BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Biogen, Inc. ("Biogen" or the "Company") (Nasdaq: BIIB) investors, concerning the Company’s and its officers’ alleged violations of federal securities laws.
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. On July 24, 2015 Biogen announced Second Quarter 2015 results and updated its full-year financial guidance decreasing revenue growth to 6% to 8% based largely on revised expectations for the growth of multiple-sclerosis drug tecfidera. The Company announced that sales of tecfidera have slowed on safety concerns following last year's report of the death of a tecfidera patient. On this news, Biogen shares dropped as much as $74.34, or 19.31%, during intraday trading on July 24, 2015.
If you purchased shares of Biogen, if you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.